4.7 Article

Abrogation of donor T-cell IL-21 signaling leads to tissue-specific modulation of immunity and separation of GVHD from GVL

Journal

BLOOD
Volume 118, Issue 2, Pages 446-455

Publisher

AMER SOC HEMATOLOGY
DOI: 10.1182/blood-2010-07-294785

Keywords

-

Categories

Funding

  1. National Institutes of Health [RO1-HL069929, RO1-CA107096, RO1-AI080455, PO1-CA33049, R01-HL095075]
  2. NHLBI
  3. Lymphoma Foundation
  4. Alex's Lemonade Stand
  5. Leukemia and Lymphoma Society
  6. Ryan Gibson Foundation
  7. Elsa U. Pardee Foundation
  8. Byrne Fund
  9. Emerald Foundation
  10. Experimental Therapeutics Center of Memorial Sloan-Kettering Cancer Center
  11. Mrs Alice Goodwin and the Commonwealth Foundation for Cancer Research

Ask authors/readers for more resources

IL-21 is a proinflammatory cytokine produced by Th17 cells. Abrogation of IL-21 signaling has recently been shown to reduce GVHD while retaining graft-versus-leukemia/lymphoma (GVL) responses. However, the mechanisms by which IL-21 may lead to a separation of GVHD and GVL remain incompletely understood. In a murine MHC-mismatched BM transplantation model, we observed that IL-21 receptor knockout (IL-21R KO) donor T cells mediate decreased systemic and gastro-intestinal GVHD in recipients of a transplant. This reduction in GVHD was associated with expansion of transplanted donor regulatory T cells and with tissue-specific modulation of Th-cell function. IL-21R KO and wild-type donor T cells showed equivalent alloactivation, but IL-21R KO T cells showed decreased infiltration and inflammatory cytokine production within the mesenteric lymph nodes. However, Th-cell cytokine production was maintained peripherally, and IL-21R KO T cells mediated equivalent immunity againstA20 and P815 hematopoietic tumors. In summary, abrogation of IL-21 signaling in donor T cells leads to tissue-specific modulation of immunity, such that gastrointestinal GVHD is reduced, but peripheral T-cell function and GVL capacity are retained. IL-21 is thus an exciting target for therapeutic intervention and improvement of clinical transplantation outcomes. (Blood. 2011; 118(2): 446-455)

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available